temozolomide lupin temozolomide 250 mg capsule bottle
southern cross pharma pty ltd - temozolomide, quantity: 250 mg - capsule, hard - excipient ingredients: iron oxide yellow; purified water; microcrystalline cellulose; colloidal anhydrous silica; sodium starch glycollate; gelatin; stearic acid; tartaric acid; titanium dioxide; iron oxide red; iron oxide black; propylene glycol; butan-1-ol; isopropyl alcohol; strong ammonia solution; ethanol absolute; ethanol; shellac; sulfuric acid - temozolomide is indicated for the treatment of:,- patients with newly diagnosed glioblastoma multiforme concomitantly with radiotherapy and then as adjuvant treatment. - recurrence of anaplastic astrocytoma and glioblastoma multiforme following standard therapy.,temozolomide is also indicated as a first-line treatment for patients with advanced metastatic malignant melanoma.
temozolomide lupin temozolomide 140 mg capsule bottle
southern cross pharma pty ltd - temozolomide, quantity: 140 mg - capsule, hard - excipient ingredients: tartaric acid; colloidal anhydrous silica; sodium starch glycollate; stearic acid; indigo carmine; microcrystalline cellulose; gelatin; purified water; titanium dioxide; propylene glycol; butan-1-ol; isopropyl alcohol; strong ammonia solution; ethanol absolute; iron oxide black; ethanol; shellac; sulfuric acid - temozolomide is indicated for the treatment of:,- patients with newly diagnosed glioblastoma multiforme concomitantly with radiotherapy and then as adjuvant treatment. - recurrence of anaplastic astrocytoma and glioblastoma multiforme following standard therapy.,temozolomide is also indicated as a first-line treatment for patients with advanced metastatic malignant melanoma.
temozolomide lupin temozolomide 20mg capsule bottle
southern cross pharma pty ltd - temozolomide, quantity: 20 mg - capsule, hard - excipient ingredients: stearic acid; microcrystalline cellulose; colloidal anhydrous silica; sodium starch glycollate; tartaric acid; lactose; purified water; gelatin; titanium dioxide; iron oxide yellow; propylene glycol; butan-1-ol; isopropyl alcohol; strong ammonia solution; ethanol absolute; iron oxide black; ethanol; shellac; sulfuric acid - temozolomide is indicated for the treatment of:,- patients with newly diagnosed glioblastoma multiforme concomitantly with radiotherapy and then as adjuvant treatment. - recurrence of anaplastic astrocytoma and glioblastoma multiforme following standard therapy.,temozolomide is also indicated as a first-line treatment for patients with advanced metastatic malignant melanoma.
temozolomide sun
sun pharmaceutical industries europe b.v. - temozolomide - glioma; glioblastoma - antineoplastic agents - temozolomide sun is indicated for the treatment of:adult patients with newly diagnosed glioblastoma multiforme concomitantly with radiotherapy (rt) and subsequently as monotherapy treatment;children from the age of three years, adolescents and adult patients with malignant glioma, such as glioblastoma multiforme or anaplastic astrocytoma, showing recurrence or progression after standard therapy.
temozolomide an temozolomide 20mg capsule bottle
southern cross pharma pty ltd - temozolomide -
temozolomide an temozolomide 5 mg capsule bottle
southern cross pharma pty ltd - temozolomide -
temozolomide an temozolomide 140 mg capsule bottle
southern cross pharma pty ltd - temozolomide -
temozolomide an temozolomide 100 mg capsule bottle
southern cross pharma pty ltd - temozolomide -
temozolomide an temozolomide 180 mg capsule bottle
southern cross pharma pty ltd - temozolomide -
temozolomide an temozolomide 250 mg capsule bottle
southern cross pharma pty ltd - temozolomide -